We note that WDR62 was previously characterized as a biomarker of resistance to AR targeted therapies in models of neuroendocrine prostate cancer (NEPC) and in NEPC patient samples however to our knowledge WDR62 has not been previously implicated as a driver of prostate cancer adenocarcinoma38. The gene discussed is AR; the disease is Familial prostate cancer.